Turkiye Klinikleri Journal of Nursing Sciences

.: REVIEW
Bulaşıcı Olmayan Hastalıkların Gelişiminde Endokrin Bozucu Maddeler: Geleneksel Derleme
Endocrine Disrupting Substances in the Development of Non-Communicable Diseases: Traditional Review
Fatma ULUSOYa, Mehmet ULUSOYb, Arzu AKCANc
aAkdeniz Üniversitesi Sağlık Bilimleri Enstitüsü, Hemşirelik ABD, Antalya, TÜRKİYE
bSüleyman Demirel Üniversitesi, Su Bilimleri ABD, Isparta, TÜRKİYE
cAkdeniz Üniversitesi Hemşirelik Fakültesi, Hemşirelik ABD, Antalya, TÜRKİYE
Turkiye Klinikleri J Nurs Sci. 2021;13(3):725-34
doi: 10.5336/nurses.2020-79987
Article Language: TR
ÖZET
Toplumda yaygın olarak görülen obezite, diabetes mellitus (DM), hipertansiyon (HT) ve kardiyovasküler hastalıkların (KVH) prevalansı gün geçtikçe artmaktadır. Her biri, diğeri için risk faktörü olabilen bu hastalıkların ortak özellikleri kronik olmalarıdır. Birey ve ailesinin yaşam kalitesini bozan, üretkenliğini azaltan, sakatlığa ve erken yaşam yılı kaybına neden olan bu hastalıklar, toplum ekonomisine de büyük bir yük getirmektedir. Obezite ve komorbiditelerinin etiyolojisi çok faktörlüdür, ancak geleneksel nedensel faktörlerin kanıtlarına rağmen endokrin bozucu aktivitesi olan çevresel toksik maddelerin rolü yakın zamanda vurgulanmaktadır. Yeni yapılan çalışmalarda, endokrin bozucu madde (EBM) maruziyeti ile obezite, DM, HT ve KVH arasında pozitif ilişki olduğuna dair artan kanıtlar vardır. Gerçekten de çok az konsantrasyonlarda bile vücuda alınan bu EBM'ler, ciddi sağlık sorunlarına neden olabilir. Bu hastalıkların bilinen risk faktörleriyle mücadelesinde, küresel ve ulusal düzeyde yapılan önleme ve kontrol programlarına rağmen prevalanslarındaki devam eden artış, yeni bir risk faktörü olan EBM'lere dikkat çekmiştir. Avrupa Birliği tarafından belirlenmiş olan başlıca EBM'ler, bisfenol A, fitalatlar, perflorlu bileşikler, poliklorlu bifeniller, dioksinler ve furanlardır. Güncel alan ile ilgili yapılan araştırmaların, yurt dışına göre Türkiye'de çok daha az sayıda olduğu görülmektedir. Bu derlemede, EBM'lerin bulaşıcı olmayan çeşitli hastalıkların gelişimindeki rolünü değerlendirmek amaçlanmıştır.

Anahtar Kelimeler: Endokrin bozucu maddeler; obezite; diyabet; hipertansiyon; kardiyovasküler hastalıklar
ABSTRACT
The prevalence of obesity, diabetes mellitus (DM), hypertension (HT) and cardiovascular diseases (CVD), which are common in the society, is increasing day by day. The common characteristics of these diseases, each of which can be a risk factor for the other, is that they are chronic. These diseases, which impair the quality of life of the individual and her family, reduce one's productivity, cause disability and early loss of life years, also place a huge burden on the community economy. The etiology of obesity and its comorbidities is multifactorial, but despite the evidence of traditional causative factors, the role of environmental toxic substances with endocrine-disrupting activity has recently been emphasized. In recent studies, there is increasing evidence of a positive association between endocrine disrupting substance (EDS) exposure and obesity, DM, HT, and CVD. Indeed, these EDSs taken into the body even in very low concentrations can cause serious health problems. In the fight against known risk factors of these diseases, the ongoing increase in their prevalence despite the prevention and control programs carried out at the global and national level has drawn attention to the EDSs, a new risk factor. The main EDSs determined by the European Union are bisphenol A, phthalates, perfluorinated compounds, polychlorinated biphenyls, dioxins and furans. It is observed that research conducted in the current field is much fewer in Turkey than abroad. In this review, it is aimed to evaluate the role of EDSs in the development of various non-communicable diseases.

Keywords: Endocrine disrupting substances; obesity; diabetes; hypertension; cardiovascular diseases
REFERENCES:
  1. Yıldız Fendoğlu B, Koçer-Gümüşel B, Erkekoğlu P. Endokrin bozucu kimyasal maddelere ve etki mekanizmalarına genel bir bakış [A general overview on endocrine disrupting chemicals and their mechanism of action]. Hacettepe University Journal of the Faculty of Pharmacy. 2019;39(1):30-43. [Link] 
  2. Zhang HC, Xu T, Hu XL, Pang WH, Yin DQ. The distributions, removals and estrogenic effects of selected endocrine disrupting chemicals in two drinking water factories in China. J Water Health. 2013;11(1):41-50. [Crossref]  [PubMed] 
  3. Kabir ER, Rahman MS, Rahman I. A review on endocrine disruptors and their possible impacts on human health. Environ Toxicol Pharmacol. 2015;40(1):241-58. [Crossref]  [PubMed] 
  4. Buck Louis GM, Gray LE Jr, Marcus M, Ojeda SR, Pescovitz OH, Witchel SF, et al. Environmental factors and puberty timing: expert panel research needs. Pediatrics. 2008;121 Suppl 3:S192-207. [Crossref]  [PubMed] 
  5. Uğur K, Şener SY, Özkan Y. Endokrin bozucu kimyasallar ve kardiyovasküler hastalıklar [Endocrine disrupting chemicals and cardiovascular diseases]. Turkiye Klinikleri J Endocrin-Special Topics. 2016;9(3):17-22. [Link] 
  6. Nadal A, Quesada I, Tudurí E, Nogueiras R, Alonso-Magdalena P. Endocrine-disrupting chemicals and the regulation of energy balance. Nat Rev Endocrinol. 2017;13(9):536-46. [Crossref]  [PubMed] 
  7. Eren MA, Sabuncu T. Endokrin bozucular ve hipertansiyon [Endocrine disruptors and hypertension]. Turkiye Klinikleri J Endocrin-Special Topics. 2016;9(3):6-11. [Link] 
  8. Üçler R. Endokrin bozucular ve diabetes mellitus [Endorine disruptors and diabetes mellitus]. Turkiye Klinikleri J Endocrin-Special Topics. 2016;9(3):27-36. [Link] 
  9. Balcı A, Erkekoğlu P, Koçer Gümüşel B. Endokrin bozucu kimyasal maddeler ve obezite arasındaki ilişkinin değerlendirilmesi-II: poliklorlu bifeniller. [Evaluation of relationship between obesity and endocrine disrupting chemicals-II: polychlorinated biphenyls: review]. Turkiye Klinikleri J Pharm Sci. 2015;4(2):50-67. [Crossref] 
  10. Gül K, Şahin M. Endokrin bozucular ve obezite [Endocrine disruptors and obesity]. Turkiye Klinikleri J Endocrin-Special Topics. 2016;9(3):37-44. [Link] 
  11. Su TC, Hwang JS, Torng PL, Wu C, Lin CY, Sung FC. Phthalate exposure increases subclinical atherosclerosis in young population. Environ Pollut. 2019;250:586-93. [Crossref]  [PubMed] 
  12. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu. Türkiye Kalp ve Damar Hastalıkları Önleme ve Kontrol Programı Eylem Planı 2015-2020. T.C. Sağlık Bakanlığı Yayın No: 988. Ankara: Anıl Reklam Matbaa Ltd. Şti.; 2015. p.1-70. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  13. T.C. Sağlık Bakanlığı Türkiye Halk Sağlığı Kurumu Kronik Hastalıklar, Yaşlı Sağlığı ve Engelliler Daire Başkanlığı. Türkiye Bulaşıcı Olmayan Hastalıklar Çok Paydaşlı Eylem Planı 2017-2025. T.C. Sağlık Bakanlığı Yayın No: 1056. Ankara: Ankara Ofset; 2017. p.1-67. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  14. Prüss-Ustün A, Wolf J, Corvalán C, Bos R, Neira M. Preventing disease through healthy environments: a global assessment of the burden of disease from environmental risks. Geneva, Switzerland: World Health Organization; 2016. p.1-147. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  15. Wolf J, Prüss-Ustün A, Vickers C. The publıc health ımpact of chemıcals: knowns and unknowns. Geneva, Switzerland: World Health Organization; 2016. p. 1-16. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  16. World Health Organization. World Health Statistics 2019: Monitoring Health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2019. p.1-120. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  17. Rezg R, El-Fazaa S, Gharbi N, Mornagui B. Bisphenol A and human chronic diseases: current evidences, possible mechanisms, and future perspectives. Environ Int. 2014;64:83-90. [Crossref]  [PubMed] 
  18. Shankar A, Teppala S. Urinary bisphenol A and hypertension in a multiethnic sample of US adults. J Environ Public Health. 2012;2012:481641. [Crossref]  [PubMed]  [PMC] 
  19. Peters JL, Fabian MP, Levy JI. Combined impact of lead, cadmium, polychlorinated biphenyls and non-chemical risk factors on blood pressure in NHANES. Environ Res. 2014;132:93-9. [Crossref]  [PubMed] 
  20. Li XT, Yu PF, Gao Y, Guo WH, Wang J, Liu X, et al. Association between plasma metal levels and diabetes risk: a case-control study in China. Biomed Environ Sci. 2017;30(7):482-91. [PubMed] 
  21. Carwile JL, Michels KB. Urinary bisphenol A and obesity: NHANES 2003-2006. Environ Res. 2011;111(6):825-30. [Crossref]  [PubMed]  [PMC] 
  22. Darbre PD. Endocrine disruptors and obesity. Curr Obes Rep. 2017;6(1):18-27. [Crossref]  [PubMed]  [PMC] 
  23. Muscogiuri G, Barrea L, Laudisio D, Savastano S, Colao A. Obesogenic endocrine disruptors and obesity: myths and truths. Arch Toxicol. 2017;91(11):3469-75. [Crossref]  [PubMed] 
  24. Bae S, Kim JH, Lim YH, Park HY, Hong YC. Associations of bisphenol A exposure with heart rate variability and blood pressure. Hypertension. 2012;60(3):786-93. [Crossref]  [PubMed] 
  25. Bai PY, Wittert G, Taylor AW, Martin SA, Milne RW, Jenkins AJ, et al. The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environ Res. 2017;158:366-72. [Crossref]  [PubMed] 
  26. European Commission [Internet]. Erişim tarihi: 25 Şubat 2021. Endocrine Distruptors. Erişim linki: [Link] 
  27. Yaprak M, Bay F, Turgut F. Endokrin bozucular ve böbrek [Endocrine distruptors and kidney]. Turkiye Klinikleri J Endocrin-Special Topics. 2016;9(3):45-9. [Link] 
  28. The Endocrine Disruption Exchange [Internet]. Erişim tarihi: 25 Şubat 2021. TEDX list of potential endocrine disruptos; 2018. Erişim linki: [Link] 
  29. Bergman A, Heindel JJ, Jobling S, Kidd KA, Zoeller RT. State of the Science of Endocrine Disrupting Chemicals - 2012. Switzerland: World Health Organization 2013. p.1-260. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Crossref] 
  30. Zemheri F, Uğuz C. Endokrin bozucu kimyasallar: nonilfenol ve bisfenol A [Endocrine disruptive chemicals: nonylphenol and bisphenol A]. Marmara Fen Bilimleri Dergisi. 2018;30(1):71-6. [Crossref] 
  31. Yıldırım Y, Ertaş Onmaz N, Gönülalan Z, Hızlısoy H, Al S, Candemir Güngör C, et al. Bisfenoller ve fitalatların halk sağlığı üzerine etkileri [Effects of bisphenols and phthalates on public health]. Erciyes Üniv Vet Fak Derg. 2020;17(1):68-75. [Crossref] 
  32. Topal M, Arslan Topal EI. Sularda endokrin bozucu maddeler ve çevresel etkileri [Endocrine disrupting substances in waters and their environmental impacts]. International Symposium of Water and Wastewater Management. 2016;10(26):1123-27. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  33. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: The Endocrine Society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):E1-E150. [Crossref]  [PubMed]  [PMC] 
  34. Dietert RR. Effects of endocrine disrupters on immune function and inflammation. In: Darbre PD, ed. Endocrine Disruption and Human Health. 1st ed. London: Elsevier/Academic Press; 2015. p.257-72. [Crossref] 
  35. Organisation for Economic Co-operation and Development. Obesity update 2017. 2017. p.1-12. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  36. Nalbone G, Cicolella A, Laot-Cabon S. Perturbateurs endocriniens et maladies métaboliques: un défi majeur en santépublique [Endocrine disruptors and metabolic diseases: a major public health challenge]. Sante Publique. 2013;25(1):45-9. [Crossref]  [PubMed] 
  37. Petrakis D, Vassilopoulou L, Mamoulakis C, Psycharakis C, Anifantaki A, Sifakis S, et al. Endocrine disruptors leading to obesity and related diseases. Int J Environ Res Public Health. 2017;14(10):1282. [Crossref]  [PubMed]  [PMC] 
  38. Shankar A, Teppala S, Sabanayagam C. Urinary bisphenol a levels and measures of obesity: results from the national health and nutrition examination survey 2003-2008. ISRN Endocrinol. 2012;2012:965243. [Crossref]  [PubMed]  [PMC] 
  39. Oktar S, Sungur S, Okur R, Yilmaz N, Ustun I, Gokce C. The relationship between phthalates and obesity: serum and urine concentrations of phthalates. Minerva Endocrinol. 2017;42(1):46-52. [Crossref]  [PubMed] 
  40. Dong R, Zhou T, Chen J, Zhang M, Zhang H, Wu M, et al. Gender- and age-specific relationships between phthalate exposures and obesity in shanghai adults. Arch Environ Contam Toxicol. 2017;73(3):431-41. [Crossref]  [PubMed] 
  41. Song Y, Hauser R, Hu FB, Franke AA, Liu S, Sun Q. Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. Int J Obes (Lond). 2014;38(12):1532-7. [Crossref]  [PubMed]  [PMC] 
  42. Airaksinen R, Rantakokko P, Eriksson JG, Blomstedt P, Kajantie E, Kiviranta H. Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care. 2011;34(9):1972-9. [Crossref]  [PubMed]  [PMC] 
  43. Alonso-Magdalena P, Quesada I, Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol. 2011;7(6):346-53. [Crossref]  [PubMed] 
  44. Kim MJ, Pelloux V, Guyot E, Tordjman J, Bui LC, Chevallier A, et al. Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells. Environ Health Perspect. 2012;120(4):508-14. [Crossref]  [PubMed]  [PMC] 
  45. Karuranga S, Malanda B, Saeedi P, Salpea P, eds. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. p.1-168. [Link] 
  46. Türkiye İstatistik Kurumu [Internet]. Türkiye İstatistik Kurumu © 2020 [Erişim tarihi: 25 Şubat 2021]. Ölüm ve Ölüm Nedeni İstatistikleri, 2019. Erişim linki: [Link] 
  47. Bora Başara B, Soytutan Çağlar İ, Aygün A, Özdemir TA. T.C. Sağlık Bakanlığı Sağlık İstatistikleri Yıllığı 2018. Ankara: Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Bilgi Sistemleri Genel Müdürlüğü; 2019. p.1-269. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  48. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-28. [Crossref]  [PubMed]  [PMC] 
  49. Hectors TL, Vanparys C, van der Ven K, Martens GA, Jorens PG, Van Gaal LF, et al. Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function. Diabetologia. 2011;54(6):1273-90. [Crossref]  [PubMed] 
  50. Bi Y, Wang T, Xu M, Xu Y, Li M, Lu J, et al. Advanced research on risk factors of type 2 diabetes. Diabetes Metab Res Rev. 2012;28 Suppl 2:32-9. [Crossref]  [PubMed] 
  51. Kirkley AG, Sargis RM. Environmental endocrine disruption of energy metabolism and cardiovascular risk. Curr Diab Rep. 2014;14(6):494. [Crossref]  [PubMed]  [PMC] 
  52. Chevalier N, Fénichel P. Endocrine disruptors: new players in the pathophysiology of type 2 diabetes? Diabetes Metab. 2015;41(2):107-15. [Crossref]  [PubMed] 
  53. Sargis RM, Simmons RA. Environmental neglect: endocrine disruptors as underappreciated but potentially modifiable diabetes risk factors. Diabetologia. 2019;62(10):1811-22. [Crossref]  [PubMed]  [PMC] 
  54. Howard SG. Exposure to environmental chemicals and type 1 diabetes: an update. J Epidemiol Community Health. 2019;73(6):483-8. [Crossref]  [PubMed] 
  55. Ahmadkhaniha R, Mansouri M, Yunesian M, Omidfar K, Jeddi MZ, Larijani B, et al. Association of urinary bisphenol a concentration with type-2 diabetes mellitus. J Environ Health Sci Eng. 2014;12(1):64. [Crossref]  [PubMed]  [PMC] 
  56. Duan Y, Yao Y, Wang B, Han L, Wang L, Sun H, et al. Association of urinary concentrations of bisphenols with type 2 diabetes mellitus: A case-control study. Environ Pollut. 2018;243(Pt B):1719-26. [Crossref]  [PubMed] 
  57. Hwang S, Lim JE, Choi Y, Jee SH. Bisphenol A exposure and type 2 diabetes mellitus risk: a meta-analysis. BMC Endocr Disord. 2018;18(1):81. [Crossref]  [PubMed]  [PMC] 
  58. Dong R, Zhao S, Zhang H, Chen J, Zhang M, Wang M, et al. Sex differences in the association of urinary concentrations of phthalates metabolites with self-reported diabetes and cardiovascular diseases in Shanghai adults. Int J Environ Res Public Health. 2017;14(6):598. [Crossref]  [PubMed]  [PMC] 
  59. Li AJ, Martinez-Moral MP, Al-Malki AL, Al-Ghamdi MA, Al-Bazi MM, Kumosani TA, et al. Mediation analysis for the relationship between urinary phthalate metabolites and type 2 diabetes via oxidative stress in a population in Jeddah, Saudi Arabia. Environ Int. 2019;126:153-61. [Crossref]  [PubMed] 
  60. Ruiz D, Becerra M, Jagai JS, Ard K, Sargis RM. Disparities in environmental exposures to endocrine-disrupting chemicals and diabetes risk in vulnerable populations. Diabetes Care. 2018;41(1):193-205. [Crossref]  [PubMed]  [PMC] 
  61. Ehrlich S, Lambers D, Baccarelli A, Khoury J, Macaluso M, Ho SM. Endocrine disruptors: a potential risk factor for gestational diabetes mellitus. Am J Perinatol. 2016;33(13):1313-8. [Crossref]  [PubMed] 
  62. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19?1 million participants. Lancet. 2017;389(10064):37-55. Erratum in: Lancet. 2020;396(10255):886. [PubMed]  [PMC] 
  63. Peters JL, Fabian MP, Levy JI. Combined impact of lead, cadmium, polychlorinated biphenyls and non-chemical risk factors on blood pressure in NHANES. Environ Res. 2014;132:93-9. [Crossref]  [PubMed] 
  64. Park SH, Lim JE, Park H, Jee SH. Body burden of persistent organic pollutants on hypertension: a meta-analysis. Environ Sci Pollut Res Int. 2016;23(14):14284-93. [Crossref]  [PubMed] 
  65. Lu X, Xu X, Lin Y, Zhang Y, Huo X. Phthalate exposure as a risk factor for hypertension. Environ Sci Pollut Res Int. 2018;25(21):20550-61. [Crossref]  [PubMed] 
  66. Donat-Vargas C, Åkesson A, Tornevi A, Wennberg M, Sommar J, Kiviranta H, et al. Persistent organochlorine pollutants in plasma, blood pressure, and hypertension in a longitudinal study. Hypertension. 2018;71(6):1258-68. [Crossref]  [PubMed]  [PMC] 
  67. World Health Organization. Noncommunicable Diseases Country Profiles 2018. Geneva: World Health Organization; 2018. p.27-223. Erişim tarihi: 25 Şubat 2021. Erişim linki: [Link] 
  68. Han C, Hong YC. Bisphenol A, hypertension, and cardiovascular diseases: epidemiological, laboratory, and clinical trial evidence. Curr Hypertens Rep. 2016;18(2):11. [Crossref]  [PubMed] 
  69. Mariana M, Feiteiro J, Verde I, Cairrao E. The effects of phthalates in the cardiovascular and reproductive systems: A review. Environ Int. 2016;94:758-76. [Crossref]  [PubMed] 
  70. Fu X, Xu J, Zhang R, Yu J. The association between environmental endocrine disruptors and cardiovascular diseases: A systematic review and meta-analysis. Environ Res. 2020;187:109464. [Crossref]  [PubMed] 
  71. Su TC, Hwang JJ, Sun CW, Wang SL. Urinary phthalate metabolites, coronary heart disease, and atherothrombotic markers. Ecotoxicol Environ Saf. 2019;173:37-44. [Crossref]  [PubMed] 
  72. Perkins JT, Petriello MC, Newsome BJ, Hennig B. Polychlorinated biphenyls and links to cardiovascular disease. Environ Sci Pollut Res Int. 2016;23(3):2160-72. [Crossref]  [PubMed]  [PMC] 
  73. Murphy MO, Petriello MC, Han SG, Sunkara M, Morris AJ, Esser K, et al. Exercise protects against PCB-induced inflammation and associated cardiovascular risk factors. Environ Sci Pollut Res Int. 2016;23(3):2201-11. [Crossref]  [PubMed]  [PMC] 
  74. Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. Int J Obes (Lond). 2013;37(8):1036-43. [Crossref]  [PubMed] 
  75. Watkins DJ, Sánchez BN, Téllez-Rojo MM, Lee JM, Mercado-García A, Blank-Goldenberg C, et al. Phthalate and bisphenol A exposure during in utero windows of susceptibility in relation to reproductive hormones and pubertal development in girls. Environ Res. 2017;159:143-51. [Crossref]  [PubMed]  [PMC] 

Login



Contact


Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 119 - 123
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com